GlassScriptPhysician profile
Thomas M Cosgriff
NPI 1750346938
$2,406.59
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.89 · 2020: $126 · 2021: $12.40 · 2022: $527 · 2023: $747 · 2024: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,396 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.25 |
| Education | $280.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $249.54 | 2022-2024 | Trodelvy |
| Pfizer INC. | $212.86 | 2023-2024 | |
| Janssen Biotech, INC. | $198.71 | 2020-2024 | Darzalex |
| Celgene Corporation | $191.57 | 2022-2024 | Reblozyl, Pomalyst, Opdualag |
| Astellas Pharma US INC | $166.03 | 2019-2024 | Xospata, Vyloy |
| Genzyme Corporation | $149.65 | 2020-2023 | |
| Daiichi Sankyo INC. | $124.88 | 2023-2024 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $103.65 | 2022-2024 | Enhertu, Imfinzi |
| Sanofi-Aventis U.S. LLC | $95.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $92.86 | 2021-2023 | |
| Genentech USA, INC. | $90.59 | 2022-2023 | Venclexta |
| Abbvie INC. | $70.50 | 2023-2024 | Venclexta |
| Regeneron Healthcare Solutions, INC. | $61.91 | 2022-2024 | Libtayo |
| Intuitive Surgical, INC. | $55.88 | 2024 | |
| Merck Sharp & Dohme LLC | $48.73 | 2019-2024 | Welireg, Reblozyl |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $37.51 | 2022-2023 | Imbruvica |
| Amgen INC. | $36.80 | 2022 | |
| Glaxosmithkline, LLC. | $34.94 | 2023-2024 | Jemperli, Zejula |
| Lilly USA, LLC | $32.66 | 2023-2024 | Jaypirca, Verzenio |
| Mylan Institutional INC. | $29.01 | 2022-2023 | Ogivri, Fulphila |
| Seagen INC. | $26.22 | 2023 | Adcetris |
| Kite Pharma, INC. | $24.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.52 | 2019 | |
| Servier Pharmaceuticals LLC | $23.99 | 2024 | |
| Sobi, INC | $21.33 | 2023 | |
| Beigene USA, INC. | $19.01 | 2024 | Tevimbra |
| Tempus Ai, INC | $17.46 | 2024 | |
| Adc Therapeutics America, INC. | $17.20 | 2023 | |
| Alnylam Pharmaceuticals INC. | $16.21 | 2024 | Givlaari |
| Array Biopharma INC | $16.08 | 2023 | Mektovi, Lorbrena, Braftovi |
| Puma Biotechnology, INC. | $15.59 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.28 | 2024 | |
| Kyowa Kirin, INC. | $15.00 | 2020 | |
| Cti Biopharma Corp. | $14.84 | 2022 | |
| Emd Serono, INC. | $14.77 | 2024 | |
| Mirati Therapeutics, INC. | $13.88 | 2023 | Krazati |
| Karyopharm Therapeutics INC. | $13.75 | 2024 | Xpovio |
| Stemline Therapeutics INC. | $13.56 | 2023 | Orserdu |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Cosgriff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.